These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8904075)

  • 1. Infusion of (+) -MK-801 and memantine -- contrasting effects on radial maze learning in rats with entorhinal cortex lesion.
    Zajaczkowski W; Quack G; Danysz W
    Eur J Pharmacol; 1996 Feb; 296(3):239-46. PubMed ID: 8904075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Learning deficits induced by chronic intraventricular infusion of quinolinic acid--protection by MK-801 and memantine.
    Misztal M; Frankiewicz T; Parsons CG; Danysz W
    Eur J Pharmacol; 1996 Jan; 296(1):1-8. PubMed ID: 8720470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MK-801 and memantine act differently on short-term memory tested with different time-intervals in the Morris water maze test.
    Duda W; Wesierska M; Ostaszewski P; Vales K; Nekovarova T; Stuchlik A
    Behav Brain Res; 2016 Sep; 311():15-23. PubMed ID: 27180167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive dysfunction induced by sequential injection of amyloid-beta and ibotenate into the bilateral hippocampus; protection by memantine and MK-801.
    Nakamura S; Murayama N; Noshita T; Katsuragi R; Ohno T
    Eur J Pharmacol; 2006 Oct; 548(1-3):115-22. PubMed ID: 16952349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose challenge by the NMDA receptor antagonist dizocilpine exacerbates the spatial learning deficit in entorhinal cortex-lesioned rats.
    Keseberg U; Schmidt WJ
    Behav Brain Res; 1995 Mar; 67(2):255-61. PubMed ID: 7779296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptations of NMDA and dopamine D2, but not of muscarinic receptors following 14 days administration of uncompetitive NMDA receptor antagonists.
    Hesselink MB; De Boer AG; Breimer DD; Danysz W
    J Neural Transm (Vienna); 1999; 106(5-6):409-21. PubMed ID: 10443547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP.
    Zajaczkowski W; Frankiewicz T; Parsons CG; Danysz W
    Neuropharmacology; 1997 Jul; 36(7):961-71. PubMed ID: 9257940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spatial learning deficit after NMDA receptor blockade and state-dependency.
    Kretschmer BD; Fink S
    Behav Pharmacol; 1999 Jul; 10(4):423-8. PubMed ID: 10780810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells.
    Bresink I; Benke TA; Collett VJ; Seal AJ; Parsons CG; Henley JM; Collingridge GL
    Br J Pharmacol; 1996 Sep; 119(2):195-204. PubMed ID: 8886398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ca2+ inhibits the association of memantine with N-methyl-D-aspartate (NMDA) receptor-gated ion channels.
    Fujimoto M; Iida H; Homma T; Kimura I; Mori M; Hamana H
    Biol Pharm Bull; 2008 Sep; 31(9):1813-5. PubMed ID: 18758084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modifications of the behavioral profile of non-competitive NMDA receptor antagonists, memantine, amantadine and (+)MK-801 after chronic administration.
    Hesselink MB; Smolders H; De Boer AG; Breimer DD; Danysz W
    Behav Pharmacol; 1999 Feb; 10(1):85-98. PubMed ID: 10780305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices.
    Frankiewicz T; Potier B; Bashir ZI; Collingridge GL; Parsons CG
    Br J Pharmacol; 1996 Feb; 117(4):689-97. PubMed ID: 8646415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic treatment with the uncompetitive NMDA receptor antagonist memantine influences the polyamine and glycine binding sites of the NMDA receptor complex in aged rats.
    Bresink I; Danysz W; Parsons CG; Tiedtke P; Mutschler E
    J Neural Transm Park Dis Dement Sect; 1995; 10(1):11-26. PubMed ID: 8619906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation.
    Chen HS; Wang YF; Rayudu PV; Edgecomb P; Neill JC; Segal MM; Lipton SA; Jensen FE
    Neuroscience; 1998 Oct; 86(4):1121-32. PubMed ID: 9697119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NMDA receptor 2C subunit is selectively decreased by MK-801 in the entorhinal cortex.
    Lindén AM; Väsäinen J; Wong G; Castrén E
    Eur J Pharmacol; 1997 Jan; 319(1):R1-2. PubMed ID: 9030910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anxiolytic-like effects of NMDA/glycine-B receptor ligands are abolished during the elevated plus-maze trial 2 in rats.
    Bertoglio LJ; Carobrez AP
    Psychopharmacology (Berl); 2003 Dec; 170(4):335-42. PubMed ID: 13680083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral effects and anticonvulsant efficacies of low-affinity, uncompetitive NMDA antagonists in mice.
    Geter-Douglass B; Witkin JM
    Psychopharmacology (Berl); 1999 Oct; 146(3):280-9. PubMed ID: 10541728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of NMDA antagonist MK-801 on radial maze performance in Zucker rats.
    Nishiga M; Fujii Y; Sugimoto Y; Konishi M; Kamei C
    Brain Res; 2002 Sep; 950(1-2):127-9. PubMed ID: 12231236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B.
    Wenk GL; Zajaczkowski W; Danysz W
    Behav Brain Res; 1997 Feb; 83(1-2):129-33. PubMed ID: 9062671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo.
    Parsons CG; Quack G; Bresink I; Baran L; Przegalinski E; Kostowski W; Krzascik P; Hartmann S; Danysz W
    Neuropharmacology; 1995 Oct; 34(10):1239-58. PubMed ID: 8570022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.